ArticleWorld journal of gastrointestinal pharmacology and therapeutics2026
Fructose malabsorption associated with functional abdominal bloating: Case-control study.
Article in World journal of gastrointestinal pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbdominal bloating is a common symptom in patients with functional gastrointestinal disorders (FGIDs). The pathophysiology of bloating remains poorly understood. Fructose malabsorption (FM) has been implicated in the pathogenesis of various FGIDs. However, there is limited data on the role of FM in patients with functional abdominal bloating.
aimTo investigate the prevalence and predictors of FM in patients with functional bloating.
methodsThis case-control study included 70 patients with functional bloating who met the Rome III criteria and 35 healthy controls. All participants were initially tested for small intestinal bacterial overgrowth, and those who tested negative subsequently underwent a fructose hydrogen breath test (FHBT) to evaluate FM. Breath hydrogen and methane levels were measured at baseline and every 15 minutes for 3 hours. A rise in breath hydrogen or methane levels > 20 ppm above baseline was considered positive. Symptoms were recorded during the test.
resultsFM was detected in 20/70 (29%) patients with functional bloating, compared with 1/35 (3%) in healthy controls (
conclusionMore than one-fourth of patients with functional bloating had FM. Future multicentre prospective studies should evaluate the role of fructose-restricted diets in managing functional bloating.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.